Seattle Genetics Nabs $25M More From AbbVie for Souped Up Antibodies

Seattle Genetics gets $25 million from AbbVie. Here are the details.

Jan 8, 2014 at 4:31PM

Seattle Genetics (NASDAQ:SGEN) is best known for its one successful marketed cancer drug, but it has been busy working behind the scenes for years on new technologies for making souped-up antibodies against cancer. Now AbbVie (NYSE:ABBV) has agreed to pay $25 million to gain more access to some of the new technology that links targeted antibodies to potent toxins.

Seattle Genetics said today it has gotten an upfront $25 million payment from North Chicago, IL-based AbbVie, the company that markets the blockbuster arthritis drug adalimumab (Humira). The deal allows AbbVie to use the Seattle Genetics's PBD dimer technology for linking a new kind of toxin to targeted antibodies, with an ability to place the toxins at precise locations on the large Y-shaped antibodies. Scientists believe the "site-specific" binding technique may provide an advantage with manufacturing consistency and a more consistent effect against tumors.

The deal is structured to allow AbbVie to work on souped-up antibodies against an undisclosed number of biological targets for cancer drugs. Seattle Genetics will be eligible for as much as $255 million in license fees and milestone payments per target, if the AbbVie drugs reach certain development and commercial goals. If any of the drug candidates reach the market, Seattle Genetics would collect a "mid-to-high" single digit percentage royalty on each product.

AbbVie has shown increasing interest in antibody-drug conjugate technology over the years, starting when it agreed to pay $8 million upfront to Seattle Genetics in 2011. AbbVie agreed to expand the deal with a $25 million payment a year later, and has now expanded it again.

Seattle Genetics has made its name in the biotech business the past couple years with brentuximab vedotin (Adcetris). It's the first commercially successful example of a drug that combines the precise targeting capability of an antibody with a toxin that provides an extra wallop to tumors. The success was followed by the FDA approval last year of Genentech's trastuzumab emtansine (Kadcyla), which is essentially a supercharged version of its original "naked" antibody marketed as Herceptin. A wide range of competitors, at large companies and small ones, have since sought to one-up that achievement. Some are experimenting with different kinds of toxins, different linkers, or with antibody-binding technologies that provide "site-specific" conjugation, so the same number of toxins get attached to the antibody every time, and they get attached to the same spot.

Seattle Genetics stock climbed 2.7 percent today, to reach $41.07 a share at 10:44 am ET. That means the company now has a market valuation of just over $5 billion.

The Motley Fool's Top Stock for 2014

There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

This article originally appeared on Xconomy, along with:

The Motley Fool recommends Seattle Genetics. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers